Jason Campagna's most recent trade in Q32 Bio Inc. was a trade of 87,738 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc | Jason A. Campagna | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 87,738 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 87,738 | 87,738 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 70,687 | 70,687 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | A. Jason Campagna | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 70,687 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Campagna A. Jason | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 37,500 | 37,500 | - | 0 | Common Stock | |
| Q32 Bio Inc | Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 17,951 | 17,951 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Campagna Jason A. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 17,951 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Jason A. Campagna | Chief Medical Officer | 25 Mar 2024 | 70,687 | 70,687 | - | - | Stock Option (Right to Buy) | ||
| Intercept Pharmaceuticals Inc | Jason Campagna | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 19,700 | 19,700 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Jason Campagna | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 12,600 | 20,531 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Jason Campagna | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.08 per share. | 01 Oct 2020 | 112 | 8,597 (0%) | 0% | 42.1 | 4,713 | Common Stock |
| Intercept Pharmaceuticals Inc | Jason Campagna | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.41 per share. | 15 Sep 2020 | 69 | 8,709 (0%) | 0% | 43.4 | 2,995 | Common Stock |